Leerink Partnrs Has Negative Outlook for Danaher Q4 Earnings

Danaher Co. (NYSE:DHR) – Analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for Danaher in a report released on Tuesday, October 22nd. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will post earnings per share of $2.15 for the quarter, down from their prior estimate of $2.39. The consensus estimate for Danaher’s current full-year earnings is $7.59 per share.

Other equities research analysts also recently issued research reports about the company. Leerink Partners lifted their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Robert W. Baird dropped their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday. Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday. Finally, TD Cowen boosted their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Stock Down 1.0 %

DHR opened at $245.41 on Thursday. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company has a market capitalization of $181.77 billion, a P/E ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. The stock has a fifty day moving average of $270.00 and a 200-day moving average of $260.34.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter last year, the firm earned $2.02 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis.

Institutional Trading of Danaher

Institutional investors have recently added to or reduced their stakes in the stock. Tsfg LLC boosted its holdings in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher during the 1st quarter worth approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new position in shares of Danaher during the 2nd quarter worth approximately $51,000. 79.05% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,059 shares of company stock worth $8,400,897. Insiders own 11.10% of the company’s stock.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.